To date, $70 million is the highest award to a Plaintiff in the Philadelphia Risperdal litigation. Read more
Zofran is a powerful anti-nausea medication approved by the FDA for patients suffering from nausea as a side effect of chemotherapy. Read more
The New Jersey decision ignores the fact that Johnson & Johnson has admitted in internal documents that its talc powder product carries a cancer risk. Read more
The class action complaint, which was filed in May 2014, alleges that Johnson & Johnson concealed from consumers the serious risks of ovarian cancer. Read more
Johnson & Johnson worked in concert with its talc supplier, Imerys Talc America, Inc., and the cosmetic trade organization, the Personal Care Products Council. Read more
The FDA recently reclassified pelvic mesh devices such as those at issue in the suits as high-risk devices. Read more
The suit is making several claims against Johnson & Johnson and Janssen. Read more
The suit was filed against McNeil in 2011 after the child died of sepsis caused by pneumonia several days after ingesting Children's Tylenol. Read more
The FDA has finally taken steps to warn the public. While the agency was slow to act, at least it finally did so. Read more
Risperdal went on the market in 1993 after receiving approval from the FDA for the treatment of schizophrenia. Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.